Home
    • Plans Blog Contact
    Biofrontera Inc logo

    Biofrontera Inc

    BFRI
    Last price US$1.30
    Market cap US$13.1m
    12M price change 37.19%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Biofrontera Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directe Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Biofrontera Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 13, 2026

    Quarterly result summary

    Revenue was $2.4M (-8% YoY). Net loss was -$0.6M. R&D expense was $0.4M.

    Revenue $2.4M -8% YoY
    Net loss -$0.6M reported
    R&D expense $0.4M reported
    G&A expense $9.7M reported

    What changed

    • Revenue -8% YoY to $2.4M.
    • Adjusted EBITDA -97% YoY to -$0.2M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 13, 2026 SEC filing 8-K Aug 13, 2026 SEC filing 10-K/A Jul 22, 2026 Earnings release Earnings release May 14, 2026 SEC filing 10-Q May 14, 2026 SEC filing 8-K May 14, 2026 SEC filing 10-K Mar 19, 2026 SEC filing 8-K Mar 19, 2026 Earnings release Earnings release Mar 19, 2026 Earnings release Earnings release Jan 13, 2026 SEC filing 8-K Jan 13, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Biofrontera Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 0.30/5
    Biofrontera Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Biofrontera ... BFRI US$13.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.76/5
    Biofrontera Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Biofrontera ... BFRI US$13.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 1.21/5
    Biofrontera Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Biofrontera ... BFRI US$13.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Biofrontera Inc logo

    Biofrontera Inc

    US$1.30

    US$13.1m

    2.36%

    37.19%